4D Molecular Therapeutics Q2 EPS $(0.63) Beats $(0.71) Estimate, Sales $5.00K Down From $239.00K YoY
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (NASDAQ:FDMT) reported a Q2 EPS of $(0.63), beating the analyst estimate of $(0.71). However, sales dropped significantly to $5.00K from $239.00K YoY.
August 08, 2024 | 9:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
4D Molecular Therapeutics reported a Q2 EPS of $(0.63), beating the analyst estimate of $(0.71). However, sales dropped significantly to $5.00K from $239.00K YoY.
While the EPS beat analyst expectations, the significant drop in sales is concerning. The mixed results may lead to neutral short-term price movement as investors weigh the positive EPS against the negative sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100